脑膜瘤
恶性肿瘤
癌症研究
癌变
放射治疗
细胞
医学
类有机物
生物
病理
内科学
神经科学
癌症
遗传学
作者
Meng Huang,Shangcheng Xu,Yuzhe Li,Shang Li,Xiudan Zhan,Chaoyin Qin,Jun Su,Zijin Zhao,Yi He,Lanfang Qin,Wei Zhao,Wenyong Long,Qing Liu
标识
DOI:10.1002/advs.202205525
摘要
Abstract High‐grade meningioma has an unsatisfactory outcome despite surgery and postoperative radiotherapy; however, the factors driving its malignancy and recurrence remain largely unknown, which limits the development of systemic treatments. Single‐cell RNA sequencing (scRNA‐Seq) technology is a powerful tool for studying intratumoral cellular heterogeneity and revealing the roles of various cell types in oncogenesis. In this study, scRNA‐Seq is used to identify a unique initiating cell subpopulation (SULT1E1 + ) in high‐grade meningiomas. This subpopulation modulates the polarization of M2‐type macrophages and promotes meningioma progression and recurrence. A novel patient‐derived meningioma organoid (MO) model is established to characterize this unique subpopulation. The resulting MOs fully retain the aggressiveness of SULT1E1 + and exhibit invasiveness in the brain after orthotopic transplantation. By targeting SULT1E1 + in MOs, the synthetic compound SRT1720 is identified as a potential agent for systemic treatment and radiation sensitization. These findings shed light on the mechanism underlying the malignancy of high‐grade meningiomas and provide a novel therapeutic target for refractory high‐grade meningioma.
科研通智能强力驱动
Strongly Powered by AbleSci AI